Fundeni Clinical Institute

The Fundeni Clinical Institute is advancing treatment options for patients with Microsatellite Instability‑High (MSI‑H) or Mismatch Repair Deficient (dMMR) stage IV colorectal cancer, focusing on innovative immunotherapy strategies.

• Combination immunotherapy regimens targeting tumor biomarkers
• Assessment of objective response using standardized imaging criteria
• Evaluation of safety and tolerability in metastatic disease
• Exploration of biomarkers to personalize therapy selection

The goal is to improve response rates and extend survival for individuals with advanced colorectal cancer by testing new therapeutic agents alongside established checkpoint inhibitors.

Researchers at the institute are conducting a study to determine whether the novel RNA‑based drug inclisiran can lower the incidence of major adverse cardiovascular events in high‑risk patients targeted for atherosclerotic cardiovascular disease (ASCVD) prevention.

• Investigation of long‑term lipid‑lowering effects
• Measurement of cardiovascular outcomes such as heart attack, stroke, and urgent revascularization
• Placebo‑controlled design to establish efficacy
• Focus on individuals with elevated risk factors for heart disease

This research aims to demonstrate that reducing cholesterol through inclisiran can significantly decrease the risk of heart‑related events, offering a new preventive option for patients at risk of cardiovascular disease.